Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Key Points Specialty pharmaceuticals and MSOs are central to Cencora’s growth strategy, with particular emphasis on retina and oncology practices. Management expects the MSO business to remain profitable, expand through physician and tuck-in additions, and become a larger part of the company’s mix. Cencora will support clinical trials through World Courier and its physician networks but does not plan to acquire a contract research organization. The company sees its logistics and practice-management capabilities as complementary to CROs and pharmaceutical manufacturers. Capital-allocation priorities remain focused on core investment, smaller acquisitions, opportunistic share repurchases, dividend growth aligned with earnings, and maintaining a strong balance sheet. Management also reaffirmed its ongoing Walgreens relationship, citing a U.S. contract through 2029 and a Boots agreement through 2031.

Cencora NYSE: COR executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Officer Bob Mauch said Cencora’s growth is being supported by pharmaceutical innovation, demographic trends and the company’s long-standing investments in specialty distribution and related services. He described pharmaceuticals as a cost-effective healthcare intervention and said the company is positioned to help manufacturers bring complex products to market while supporting providers and patients.

“What is the driver of that growth is really the positioning that we have within the specialty pharmaceutical market,” Mauch said. “You have this amazing innovation that’s happening in pharma.” Mauch said the company has spent more than two decades investing, competing and building capabilities in specialty care. Those capabilities include specialty distribution, group purchasing organization services and medical specialty organizations, or MSOs. He said Cencora aims to provide support in the background so providers can focus on patient care.

Chief Financial Officer Eva Boratto, who joined Cencora near the end of June, said her decision to return to healthcare followed a career spanning pharmaceutical manufacturer Merck, Medco and CVS Health. She said her prior experience with Medco gave her familiarity with Cencora because Medco had been among the company’s largest customers at the time. Boratto said Cencora’s strategy and role in the pharmaceutical market were key attractions. She also said the evolving regulatory environment required learning, but did not deter her from taking the position.

“The strategy that Bob has put together is so clear,” Boratto said. “The importance of the role that we will play in the pharmaceutical space just excites me every day.” She said the finance organization has substantial depth of talent and noted the support she received during the transition from former CFO Jim Cleary. Boratto also said she had underestimated, in a positive sense, the breadth of Cencora’s services beyond logistics and distribution. Those services support hospital accounts, corporate partners and pharmacy partners, she said, with the goal of enabling those customers to grow.

Mauh said Cencora expects its MSO business to remain a profitable and growing part of the company and to cont...